An improved method to generate megakaryocytes from human induced pluripotent stem cells
10.13303/j.cjbt.issn.1004-549x.2022.09.004
- VernacularTitle:一种人诱导多能干细胞分化生成巨核细胞的优化方案
- Author:
Weihua HUANG
1
;
Haihui GU
1
;
Yang ZANG
1
;
Yue YANG
1
;
Zhanshan CHA
1
;
Yanxin LI
2
;
Baohua QIAN
1
Author Information
1. Department of Transfusion Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China
2. Department of Hematology & Oncology, Shanghai Children′s Medical Center, School of Medicine, Shanghai Jiao Tong University, National Health Committee Key Laboratory of Pediatric Hematology & Oncology
- Publication Type:Journal Article
- Keywords:
human induced pluripotent stem cells;
megakaryocytes;
improved method
- From:
Chinese Journal of Blood Transfusion
2022;35(9):900-903
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To optimize the existing spin-EB method and promote human induced pluripotent stem cells (hiPSCs) differentiate into megakaryocytes (MKs). 【Methods】 In this study, the initial inoculation amount of hiPSCs was increased from 3 500 cells/well to 8 000 cells/well, and the size of EB was increased. By observing the generation time of EB- hematopoietic cells during differentiation, and detecting the proliferation of CD34+ hematopoietic progenitor cells and CD41+ MKs in different stages, it was studied whether the optimized scheme could promote the differentiation of hiPSCs into hematopoietic progenitor cells(HPCs) and MKs. 【Results】 By increasing the initial inoculation amount of hiPSCs and the size of EB, the differentiation of hiPSCs into HPCs and MKs and the cell production efficiency can be promoted. 【Conclusion】 Our research describes an optimized and repeatable differentiation method, which can produce hematopoietic progenitor cells and mature MKs from hiPSCs in a relatively short time with higher yield. It is of great clinical significance and broad scientific research prospect to continuously optimize the culture scheme of hiPSCs differentiation to produce MKs and platelets in vitro, and to promote large-scale platelet generation in vitro in transfusion medicine.
